Skip to main content
TiumBio Co., Ltd. logo

TiumBio Co., Ltd. — Investor Relations & Filings

Ticker · 321550 ISIN · KR7321550006 KO Professional, scientific and technical activities
Open in API
Filings indexed 296 across all filing types
Latest filing 2020-03-09 Regulatory Filings
Country KR South Korea
Listing KO 321550

About TiumBio Co., Ltd.

http://www.tiumbio.com/en/

TiumBio is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics for rare and incurable diseases. The company's pipeline targets conditions with high unmet medical needs, including fibrotic diseases, cancer, and rare hematological disorders. Its lead assets include Merigolix (TU2670), an oral GnRH antagonist in clinical development for endometriosis and uterine fibroids, and TU7710, a long-acting recombinant activated factor VII for hemophilia. TiumBio also develops small molecule antagonists targeting the TGF-β signaling pathway for applications in oncology and fibrosis. The company advances its programs through clinical development and strategic global partnerships.

Recent filings

Filing Released Lang Actions
주주총회집중일개최사유신고
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company is holding its AGM on a date that coincides with other companies, which is a specific regulatory disclosure requirement in the Korean market. Since it does not fit into the specific categories of AGM materials, proxy statements, or voting results, and is a standard regulatory disclosure, it falls under the RNS (Regulatory Filings) category.
2020-03-09 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for TiumBio. It contains the meeting agenda, details on board activities, and financial statements (balance sheet, income statement, etc.) intended for shareholder review prior to the meeting. In the context of financial filings, this document is a Proxy Solicitation & Information Statement (PSI) as it provides shareholders with the necessary information to vote on agenda items, including director appointments and financial approvals.
2020-03-09 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Management Reports Classification · 95% confidence The document is a regulatory filing from a Korean company (TiumBio) announcing a significant change (over 30%) in its financial structure (revenue, operating profit, net income) compared to the previous fiscal year. This is a standard 'Earnings Release' or 'Financial Results Announcement' required by the Korea Exchange (KRX) for listed companies to disclose preliminary financial performance before the final audit is completed. It fits the definition of an Earnings Release (ER) as it provides key financial highlights and the reasons for the variance.
2020-01-31 Korean
기타경영사항(특허권취득)(자율공시)(응고인자 VII의 융합 단백질을 포함하는 안정성이 개선된 약학적 조성물)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent (특허권 취득) by TiumBio. It details the patent name, content, and its application in the company's drug development program. Since this is a regulatory announcement of a specific corporate event that does not fall into financial reporting, M&A, or governance categories, it is classified as a general regulatory filing.
2019-12-18 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties (directors/executives) of TiumBio. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema, as it tracks significant ownership thresholds and changes.
2019-12-12 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/Korea Exchange). This type of filing is specifically used to disclose insider transactions, such as stock option exercises or purchases/sales of shares by company directors and executives. In the provided taxonomy, this corresponds to 'Director's Dealing'.
2019-12-12 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.